The US FDA has accepted the New Drug Application (NDA) for Basilea's antibiotic ceftobiprole and set 3 April 2024 as the Prescription...

We publish a research report today on Basilea examining the recent performance and the outlook as the company enters an important period...

Basilea has reached profitability earlier than expected and has a strong balance sheet and high prospects within its anti-infectives...